logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Fulltext. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes.

    Article - En anglais

    Fulltext.

    Evidence documenting the safety of acid-suppressing drugs in pregnancy is very limited.

    The authors assessed the prevalence of congenital malformations in first trimester-exposed pregnancies to cimetidine, omeprazole, and ranitidine and compared it with nonexposed pregnancies between 1991 and 1996.

    Two different sources were used, the United Kingdom General Practice Research Database and the Italian Friuli-Venezia Giulia Health Database.

    The final study cohort included 1,179 pregnancies from the United Kingdom and 1,057 from Italy.

    Abortions or ectopic pregnancies were not included.

    There were 20 stillbirths and 2,261 live-born babies in both cohorts combined, with 100 offspring identified with a malformation.

    The overall malformation rate was 4.4%. The relative risks for nongenetic congenital malformations associated with the use of cimetidine, omeprazole, and ranitidine were 1.2 (95% confidence interval (Cl) : 0.6,2.3), 0.9 (95% Cl : 0.3,2.2), and 1.4 (95% Cl : 0.8,2.4), respectively, compared with the nonexposed.

    No specific grouping in the distribution of malformations was observed in any of the three exposed groups.

    Moreover, no relation was found between drug exposure and preterm delivery or growth retardation.

    These findings suggest that the use of acid-suppressing drugs during the first trimester of pregnancy is not associated with a major teratogenic risk.

    Mots-clés Pascal : Cimétidine, Antiulcéreux, Antisécrétoire, Antihistaminique, Antagoniste, Récepteur histaminergique H2, Oméprazole, Inhibiteur enzyme, Inhibiteur pompe proton, Benzimidazole dérivé, Ranitidine, Gestation, Premier trimestre, Toxicité, Malformation, Maladie congénitale, Prévalence, Nouveau né pathologie, Nouveau né, Homme, Etude comparative, Epidémiologie, Royaume Uni, Europe

    Mots-clés Pascal anglais : Cimetidine, Antiulcer agent, Antisecretory agent, Antihistaminic, Antagonist, H2 Histamine receptor, Omeprazole, Enzyme inhibitor, Proton pump inhibitor, Benzimidazole derivatives, Ranitidine, Pregnancy, First trimester, Toxicity, Malformation, Congenital disease, Prevalence, Newborn diseases, Newborn, Human, Comparative study, Epidemiology, United Kingdom, Europe

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0450204

    Code Inist : 002B02U10. Création : 22/03/2000.